Lantheus Holdings, Inc. announced that the FDA has approved Pylarify, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis… read more.
Myovant Sciences announced the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for relugolix for the treatment of advanced prostate cancer. The validation of the… read more.
Professor Ahmed gives an overview of one of the sessions in the BTOG Translational Oncology Symposium.
Men who have received initial treatment for prostate cancer with abiraterone added to hormone therapy achieved a survival rate 37 per cent higher than those not treated with… read more.
Survival was more than 2 years shorter in breast, prostate cancers. Patients with rheumatoid arthritis (RA) had a 40% to 50% increased mortality risk if they developed breast… read more.
Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.
Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.
by Gary Finnegan: Good news in the battle against cancer: death rates from leukaemia among people of all ages in Europe are falling.
by Maria Dalby: Advances in diagnostic techniques, genetic testing and immunosuppressive protocols allow clinicians to tailor interventions to the individual patient’s needs to a greater extent than in… read more.
by Bruce Sylvester: Men who have had a heart attack and then receive androgen deprivation therapy (ADT) for prostate cancer are at an increased risk of subsequent fatal… read more.
Men with asthma are less likely to have aggressive prostate cancer or to die from the disease, according to a large, prospective cohort study published in the International… read more.
Firmagon (Degarelix) is a competitive, reversible GnRH receptor blocker, for patients with advanced hormone-dependent prostate cancer. Where Injection technique is critical; Nora Sullivan, a specialist nurse at Hibernian… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
